Retro Biosciences, founded with the mission to extend healthy human lifespan by 10 years, focuses on cellular reprogramming and plasma-inspired therapeutics. The American medical firm aims to develop therapies that meaningfully reverse age-related diseases by targeting the underlying mechanisms of aging. Their market focus is on addressing the root causes of age-related diseases, which account for a significant portion of healthcare spending in the U.S. and globally.
Notable affiliated individuals and investors include prominent figures in the biotech and medical research fields. Retro Biosciences has achieved significant milestones in advancing age-reversal therapies, positioning itself as a leader in the longevity sector. The company's impact is reflected in its innovative approach to combating age-related diseases, potentially transforming healthcare by reducing the prevalence and severity of these conditions.
